DEMETRIUS COOK: Open Payments
NPI 1003482993 · OLIVE BRANCH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$775 in 34 payments from 9 companies in 2025. Trend: 2023 $901 · 2024 $335 · 2025 $775
Food & beverage: $775
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 5 | $215 |
| ABBVIE INC. | 12 | $197 |
| Otsuka America Pharmaceutical, Inc. | 5 | $142 |
| Axsome Therapeutics, Inc. | 4 | $68 |
| Alkermes, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Lundbeck LLC | 1 | $19 |
| Tris Pharma Inc | 1 | $15 |
Products named: Qelbree, VRAYLAR, REXULTI, Auvelity, ARISTADA, TRINTELLIX, SPRAVATO, Dyanavel XR.
Industry payments across MS — which companies pay providers there.
